Close Menu

NEW YORK (360Dx) – Chembio Diagnostics said today that it has received CE marking for its DPP HIV-Syphilis combination assay — a single-use, point-of-care test for the detection of antibodies to HIV 1 and 2 and Treponema pallidum, the causative agent of syphilis.

The assay — cleared for marketing within the member states of the European Union, and the Caribbean region except for Puerto Rico — runs on the firm's Dual Path Platform chromatographic immunoassay technology, which has significant advantages over lateral flow technologies, Chembio said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

Sponsored by

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.


This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.